0RDB.L - Oryzon Genomics S.A.

LSE - LSE Prezzo differito. Valuta in EUR.
2,0950
+0,0146 (+0,70%)
Al 08:00AM BST. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente2,0804
Aperto2,0950
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,0950 - 2,0950
Intervallo di 52 settimane2,0200 - 2,9750
Volume5
Media Volume779
Capitalizzazione765.456
Beta (5 anni mensile)0,97
Rapporto PE (ttm)N/D
EPS (ttm)-0,0880
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

    Selected for Oral PresentationStudy done in the CMT1A mouse modelSupported by the CMT Research Foundation MADRID, Spain and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today that it will present positive preclinical efficacy data of ORY-4001 in a CMT model at the 2023 Peripheral Nerve Society (PNS) Annual

  • GlobeNewswire

    ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting

    MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced the presentation of the trial in progress (TIP) FRIDA poster entitled Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia at the upcoming American Society of Clinical Oncolo

  • GlobeNewswire

    ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2023

    Positive results from interim analysis of vafidemstat's PORTICO Phase IIb trial in Borderline Personality DisorderRecruiting patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant AML patients ORY-4001, a selective HDAC-6 inhibitor, nominated as clinical development candidate for neurological diseases such as Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS) and others MADRID, Spain and BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Or

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in May-June

    BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023 MADRID and BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several internat

  • GlobeNewswire

    ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder

    Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial MADRID, Spain and BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for b

  • GlobeNewswire

    ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients

    In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib

  • GlobeNewswire

    ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders

    A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development c

  • GlobeNewswire

    ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology

    Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici (Adams Clinical & Copley Clinical), Dr. med. Peter Hahn (Investigator & Neurology Specialist, emovis), and Dr. Olga Salame

  • GlobeNewswire

    ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

    Strong clinical progress in both oncology and CNS Cash, cash equivalents and marketable securities totaled $22.7 million as of December 31, 2022 MADRID, Spain and BOSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter ended December 31, 2022 and provided an update on rece

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in February-March

    BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer Epigenetics Institute Symposium: From Genes to Chromatin to Therapeutics BioCapital Europe 2023BIO-EUROPE Spring 2023SmallCap Event MADRID, Spain and BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unme

  • GlobeNewswire

    ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

    Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a broad collaboration with The Cancer Epigenetics Institute (CEI) MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the f

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in January

    6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2023 MADRID, Spain and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress

  • GlobeNewswire

    ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches

    Eurostars-3 collaborative project with Danish institutions ImProTher and University of Copenhagen Global budget of 1.4 million euros; Oryzon to receive up to 400,000 euros Project will assess the efficacy of iadademstat in combination with checkpoint inhibitors and/or oncological vaccines MADRID, Spain and BOSTON, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseas

  • GlobeNewswire

    ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022

    Robust, rapid and durable efficacy - ORR 81%, of which 64% are CR/CRi68% of CR/CRi lasting more than 6 monthsLongest remission + 3 yearsIadademstat and azacitidine combination shows a good safety profile Dosing of iadademstat established at 90 μg/m2/dResponses in patients with a diverse array of AML mutations, including FLT3 or TP53 mutations, and in monocytic AML subtypes MADRID, Spain and BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical

  • GlobeNewswire

    ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

    Collaborative study with Fox Chase Cancer Center (FCCC)Oryzon and FCCC will collaborate to assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs MADRID and SPAIN and BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the FDA has approved the Investigational New Drug (IND) a

  • GlobeNewswire

    ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference

    Final data of Phase II ALICE trial in unfit AML patients treated with iadademstat and azacitidineMADRID, Spain and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that its communication reporting final data from its ongoing and fully accrued Phase IIa ALICE trial, investigating iadademstat in combination

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in November

    Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022 MADRID, Spain and BOSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several intern

  • GlobeNewswire

    ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022

    Strong clinical progress in both oncology and CNSMADRID, Spain and BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2022 and provided an update on recent developments. Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “We continued progressing on our clinic

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in October

    Chardan's 6th Annual Genetic Medicines Conference MSD European Business Development Outreach Iberian Digital Forum AACR Special Conference: Cancer Epigenomics Brain Innovation Days HealthTech Innovation Days BIO-Europe 2022 34th EORTC-NCI-AACR Symposium MADRID, Spain and BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, a

  • GlobeNewswire

    ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

    At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23 MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents initial preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderli

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in September

    H.C. Wainwright Global Investment Conference10th European Conference on Mental HealthSachs Annual Biotech in Europe ForumAnnual RAS-Targeted Drug Development SummitXIX Congress of the Spanish Society of Psychogeriatrics MADRID, Spain and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its managemen

  • GlobeNewswire

    ORYZON Collaborates with the CMT Research Foundation in the US

    To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth diseaseCMTRF to provide funding for in vivo efficacy tests in CMT preclinical model MADRID and BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patien

  • GlobeNewswire

    ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022

    Oryzon invests $8.1 million in R&D in the first half 2022MADRID, Spain and BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2022 and provided an update on recent developments. Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “We continued to make strong progr

  • GlobeNewswire

    ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers

    Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and solid tumors MADRID, Spain and BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the

  • GlobeNewswire

    ORYZON Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €20 Million Over 30 Months

    Funding provided by Nice & Green SA, a Swiss institutional investor To extend its cash runway and continue the ongoing Clinical Trials in oncology and CNSInitial execution of the First tranche of €8 Million, plus three optional additional tranches of €4Million to be executed in the future, at Oryzon’s request, subject to customary conditions MADRID, Spain and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutic